RALP as a first-line treatment for high-risk, localized and locally advanced prostate cancer

Posted on November 3, 2011 by Sitemaster

In light of the publication this week of data by Warde et al. on external beam radiation therapy + lifelong total androgen deprivation (ADT) as a first-line treatment for high-risk, localized and locally advanced prostate cancer (click here for commentary), it is interesting to note an article from another research group outlining experience with a [...]

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: , , , , | Leave a Comment »

EBRT + total (combined) ADT in treatment of high-risk, localized and locally advanced prostate cancer

Posted on November 3, 2011 by Sitemaster

The big news today is the publication, in The Lancet, of the interim results of the NCIC CTG PR.3/MRC UK PR07 trial, originally presented by Warde et al. at the annual meeting of the American Society for Clinical Oncology in June 2010 and then by Mason et al. at the annual meeting of the American [...]

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: , , , , , , | Leave a Comment »

Mortality and management of locally advanced prostate cancer with non-curative intent

Posted on June 30, 2011 by Sitemaster

A fascinating new paper based on data from the Prostate Cancer DataBase Sweden provides important insight into the consequences of delayed diagnosis and potential under-treatment of men who are diagnosed with locally advanced prostate cancer.

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: , , , , | 14 Comments »

Prostate cancer-specific mortality after non-curative treatment of locally advanced disease

Posted on June 1, 2011 by Sitemaster

A new analysis of information from the Swedish national prostate cancer registry database and the Swedish cause of death register has confirmed the importance of aggressive, curative treatment of men with locally advanced prostate cancer.

Filed under: Living with Prostate Cancer, Management | Tagged: , , , | 1 Comment »

First-line surgical management of high-risk, localized and locally advanced prostate cancer

Posted on October 22, 2010 by Sitemaster

For many years surgery was considered to be inappropriate for most men with locally advanced prostate cancer — most particularly those with positive lymph nodes (TxN1Mx) at the time of surgery.

Filed under: Diagnosis, Management, Treatment | Tagged: , , , , | Leave a Comment »

Does local therapy with ADT for locally advanced prostate cancer improve patient outcomes?

Posted on August 5, 2010 by Sitemaster

The use of androgen deprivation therapy (ADT) is at the heart of treatment for patients with advanced forms of prostate cancer. What has been debated for years, however, is when, for how long, and in combination with what other forms of therapy ADT should be applied.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 9 Comments »

Neoadjuvant chemohormonal therapy in high-risk prostate cancer patients

Posted on January 14, 2010 by Sitemaster

It is clear from a report in the December issue of Urologic Oncology that the neoadjuvant use of chemohormonal therapy prior to surgery or radiation is not going to be a “cure-all” for prostate cancer patients initially diagnosed with high-risk, locally advanced prostate cancer.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , | Leave a Comment »

Duration of hormone therapy in combination with radiation for locally advanced prostate cancer

Posted on June 11, 2009 by Sitemaster

An important article by Bolla et al. has been published in the New England Journal of Medicine today, together with editorial comment by Albertsen. We advise readers to study this article in conjunction with a second article published today under the heading “Hormone therapy and radiation treatment: a topical update.”

Filed under: Management, Treatment | Tagged: , , , , | Leave a Comment »

Neoadjuvant paclitaxel before surgery in high risk, locally advanced patients

Posted on March 20, 2009 by Sitemaster

A group at the Cleveland Clinic has reported the results of a small, single-arm, Phase II trial of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel or neoadjuvant Abraxane®), given prior to radical prostatectomy in high risk, locally advanced patients. Prior comparable studies with neoadjuvant docetaxel have demonstrated a PSA response but have shown no obvious antitumor activity.

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | Leave a Comment »

Follow

Get every new post delivered to your Inbox.

Join 269 other followers